Summary
Alnylam Pharmaceuticals, Inc. (ALNY) filed an 8-K report on May 9, 2006, primarily to announce its financial results for the first quarter ended March 31, 2006. This filing serves as an official notification to investors regarding the company's operational and financial performance during the period. While the 8-K itself does not contain the detailed financial figures, it directs stakeholders to a press release (Exhibit 99.1) for comprehensive information on the company's results of operations and financial condition. Investors should refer to this accompanying press release for specifics on revenue, expenses, net income/loss, and balance sheet items as of the reporting date. The filing indicates that the information furnished is not considered "filed" under Section 18 of the Exchange Act, meaning it does not carry the same legal implications as a standard filing.
Key Highlights
- 1Announcement of Q1 2006 financial results on May 9, 2006.
- 2Press release containing detailed financial results furnished as Exhibit 99.1.
- 3Filing confirms the company's operational and financial status as of March 31, 2006.
- 4Information provided is furnished, not officially 'filed' under Section 18 of the Exchange Act.
- 5The report serves as a key communication channel for investors regarding company performance.